Edition:
United States

Kyowa Hakko Kirin Co Ltd (4151.T)

4151.T on Tokyo Stock Exchange

2,156JPY
2:00am EDT
Change (% chg)

¥-33 (-1.51%)
Prev Close
¥2,189
Open
¥2,178
Day's High
¥2,186
Day's Low
¥2,150
Volume
828,300
Avg. Vol
1,036,110
52-wk High
¥2,478
52-wk Low
¥1,785

Chart for

About

Kyowa Hakko Kirin Co., Ltd. is mainly engaged in medical product and Biochemical businesses. The Medical Product segment is engaged in the manufacture, sale and sales promotion of ethical drug and reagent for clinical test, the development of candidate substances for new drugs, as well as the research and development of... (more)

Overall

Beta: 0.78
Market Cap(Mil.): ¥1,261,923.00
Shares Outstanding(Mil.): 576.48
Dividend: 15.00
Yield (%): 1.23

Financials

  4151.T Industry Sector
P/E (TTM): 22.68 28.88 32.86
EPS (TTM): 96.52 -- --
ROI: 8.42 13.55 13.13
ROE: 8.62 15.28 15.07

BRIEF-Aevi Genomic Medicine Expands Collaboration With Kyowa Hakko Kirin Co

* AEVI GENOMIC MEDICINE INC - EXPANDED COLLABORATION WITH KYOWA HAKKO KIRIN CO LTD

Mar 07 2018

BRIEF-Kyowa Kirin, Ultragenyx Announce Crysvita Receives Conditional Marketing Authorization In Europe For The Treatment Of X–Linked Hypophosphatemia In Children

* KYOWA KIRIN AND ULTRAGENYX ANNOUNCE CRYSVITA® (BUROSUMAB) RECEIVES CONDITIONAL MARKETING AUTHORIZATION IN EUROPE FOR THE TREATMENT OF X–LINKED HYPOPHOSPHATEMIA IN CHILDREN

Feb 23 2018

BRIEF-Kyowa Hakko Kirin appoints KPMG AZSA LLC as new corporate auditor

* Says it appoints KPMG AZSA LLC as new corporate auditor, to replace Ernst & Young ShinNihon LLC, effective March 23

Feb 21 2018

Earnings vs. Estimates